Episode Details
Back to Episodes
Guardant Soars as Sector Holds Strong
Description
The testing and diagnostics sector delivered a strong first-quarter performance, with revenues up 3% above expectations, fueled by an aging population and rising demand for preventive care. Guardant Health soared as the standout, with nearly 50% year-over-year revenue growth and a 45% stock surge, thanks to breakthrough liquid biopsy technology. Meanwhile, RadNet missed earnings despite a 22% revenue beat, weighed down by weather disruptions — its stock fell 9%. Labcorp, NeoGenomics, and Quest Diagnostics all exceeded targets, reinforcing the sector’s resilience amid pricing pressures and regulatory challenges, while AI and personalized medicine continue to drive future growth.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/dcd2f778b149f406